Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Venglustat SCHEMBL19844439 | 0.92 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL12615329 | 0.92 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL12615333 | 0.92 | NTMT1 (1.00) | NTMT1UGCG | |
| Venglustat SCHEMBL29359568 | 0.92 | NTMT1 (1.00) | NTMT1UGCG | |
| SCHEMBL19407265 | 0.91 | NTMT1 (1.00) | NTMT1UGCG | |
| SCHEMBL15579449 | 0.86 | NTMT1 (0.81) | NTMT1UGCG | |
| SCHEMBL19837241 | 0.85 | NTMT1 (0.80) | NTMT1UGCG | |
| Venglustat SCHEMBL31522597 | 0.83 | NTMT1 (0.83) | NTMT1UGCG | |
| Venglustat SCHEMBL29358474 | 0.83 | NTMT1 (0.83) | NTMT1UGCG | |
| SCHEMBL29386898 | 0.80 | NTMT1 (0.72) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160361301-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361301-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 763/4885UGCG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.